NCCN 2014 Congress Series™: Non-Small Cell Lung Cancer

Boston, MA US
October 25, 2014

Lung cancer is the leading cause of cancer death in the United States. Oncologists need to be aware of new treatment options and recommendations so they can implement the best treatment plans and thus improve outcomes for their patients with lung cancer. The 2014 NCCN Congress Series™: Non-Small Cell Lung Cancer will discuss the most recent developments in diagnosis and treatment to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with non-small cell lung cancer.

View agenda

View fees

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other healthcare professionals who manage patients with non-small cell lung cancer.

Learning Objectives

Following this activity, participants should be able to: 

New Recommendations for Lung Cancer Screening and Follow-up

  • Outline the criteria for assessing whether patients are at high risk for lung cancer and thus are candidates for lung cancer screening
  • Describe the benefits and risks of lung cancer screening
  • Apply the currently recommended NCCN screening and follow-up guidelines for lung cancer

Biomarkers and Testing In Lung Cancer

  • Describe the benefits of molecular testing of tumor tissue as it relates to more appropriate selection of therapy and better outcomes
  • Discuss the appropriate use of different types of minimally invasive techniques that may be used to obtain tissue samples for molecular testing
  • Analyze current recommendations regarding molecular testing for anaplastic lymphoma kinase (ALK) rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations

Treatment of Advanced Disease

  • Explain the most appropriate first-line, maintenance, second-line, and third-line therapies in patients with lung cancer, including those with specific driver mutations
  • Describe the factors related to the selection of maintenance therapy for lung cancer patients
  • Indicate the optimal therapeutic management of patients with sensitizing EGFR mutations and ALK gene rearrangements
Additional information
Supporters: 

Supported by educational grants from:

  • Astellas Scientific and Medical Affairs, Inc. and Genentech
  • Foundation Medicine, Inc.
  • Lilly
  • Novartis Oncology

This program is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 3.00 Participation
  • 3.00 Nurse
  • 3.00 Pharmacist
  • 3.00 Physician
Course opens: 
10/23/2014
Course expires: 
12/23/2014
Event starts: 
10/25/2014 - 7:30am EDT
Event ends: 
10/25/2014 - 12:00pm EDT
Cost:
$0.00
Add to calendar: 
Massachusetts General Hospital Cancer Center
55 Fruit Street
O'Keeffe Auditorium
Boston, MA 02114
United States

Ella Kazerooni, MD
University of Michigan Comprehensive Cancer Center

Gregory A. Otterson, MD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

Jyoti D. Patel, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information

Available Credit

  • 3.00 Participation
  • 3.00 Nurse
  • 3.00 Pharmacist
  • 3.00 Physician

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing